Radnostix, Inc.

What they do

Radnostix operates through four active segments: Theranostics Products, Cobalt Products, Calibration & Reference Products, and Medical Devices, plus a Fluorine Products segment under strategic review. The Theranostics segment produces an FDA-approved generic sodium iodide I-131 drug for hyperthyroidism and thyroid cancer, radiochemicals like Tb-161, and cGMP APIs. Calibration & Reference Products sells sealed source standards to nuclear pharmacies, imaging clinics, and industrial users, while Cobalt Products supplies cobalt-60 for medical, research, and industrial applications. Medical Devices currently resells third-party products and is developing its own I-131 encapsulation system, Radvent devices, and the Lara and Ellexa systems acquired from Lucerno Dynamics.

Revenue drivers

• Theranostics Products — Largest segment by revenue; includes the FDA-approved generic sodium iodide I-131 drug, radiochemicals, and cGMP APIs. Company cites BCC Research that the theranostics market was $4.3B in 2024 and is expected to reach $12.7B by 2029.
• Calibration & Reference Products — Produces sealed source calibration and reference standards sold to nuclear pharmacies, imaging clinics, hospitals, labs, and industrial settings, and also sells bulk isotopes.
• Cobalt Products — Produces cobalt-60 products for medical, research, and industrial applications by irradiating cobalt-59.
• Medical Devices — Currently resells third-party products and is developing proprietary devices including an I-131 encapsulation system, Radvent devices, and the Lara and Ellexa systems acquired from Lucerno Dynamics.

Recent performance

Annual revenue declined to $13.1M in 2025 from $13.9M in 2024, and net income swung to a loss of $908,002 from net income of $8,574 in 2024. Operating cash flow stayed positive at $620,163 in 2025. Quarterly revenue fell from $3.3M in the quarter ended September 30, 2025 to $2.9M in December 31, 2025, then to $2.4M in March 31, 2026, before recovering to $2.7M in June 30, 2026. At June 30, 2026, total assets were $16.6M, total liabilities $14.8M, and shareholder equity $1.9M, leaving a thin equity base.

Strategy

Management operates across five reportable segments and is focused on growing the Theranostics Products segment, which it identifies as the largest by revenue. The company is developing proprietary medical devices, including an I-131 encapsulation system, Radvent devices, and the Lucerno Dynamics assets (Lara and Ellexa systems). For the Fluorine Products segment, management states it is evaluating fundraising, joint venturing, or divesting those assets. The company has been active in corporate transactions, including a material agreement and acquisition/disposition reported on July 1, 2026, and a director/officer change and shareholder vote reported on July 21, 2026.

Risks

• Thin equity and high leverage — Shareholder equity was just $1.9M against $14.8M in total liabilities at June 30, 2026, and long-term debt stood at $1.9M at December 31, 2025, leaving limited financial cushion.
• Recurring net losses — The company reported net losses in three of the last five years, including $908,002 in 2025, demonstrating volatile profitability.
• Revenue concentration and decline — Revenue fell to $13.1M in 2025 from $13.9M in 2024, and the Theranostics segment is the largest by revenue, creating concentration risk.
• Regulatory and competitive pressure — The company operates in highly regulated nuclear medicine and radiopharmaceutical markets, faces competition for most radiochemicals, and relies on FDA compliance for its generic sodium iodide I-131 product.

Outlook

Management believes the company is well positioned to serve the growing radioisotope and radiopharmaceutical market. It is evaluating strategic alternatives for the Fluorine Products segment, including fundraising, joint venturing, or divestiture. The company continues development of proprietary medical devices and expansion of its Theranostics offerings, including Tb-161 and cGMP API supply for third-party clients.